GFM
AMLX icon

GF Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

GF Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8K Sell
2,326
-129
-5% -$2K ﹤0.01% 408
2026
Q1 		$34.1K Buy
2,455
+297
+14% +$4.18K ﹤0.01% 445
2025
Q4 		$26.1K Buy
2,158
+240
+13% +$3.26K ﹤0.01% 478
2025
Q3 		$26.1K Buy
1,918
+218
+13% +$2.05K ﹤0.01% 460
2025
Q2 		$10.9K Hold
1,700
– – ﹤0.01% 562
2025
Q1 		$6.02K Buy
1,700
+261
+18% +$929 ﹤0.01% 612
2024
Q4 		$5.44K Buy
+1,439
New +$6.77K ﹤0.01% 607

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GF Fund Management's AMLX Position: Q2 2026 in Review

GF Fund Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 5.3% in Q2 2026, selling an estimated $2K and leaving 2,326 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #408.

GF Fund Management first reported a position in AMLX in Q4 2024 and has held it in 7 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • GF Fund Management held 2,326 shares of Amylyx Pharmaceuticals worth $41.8K as of Q2 2026.
  • GF Fund Management sold 129 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $2K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #408 holding.
  • GF Fund Management first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.